Purdue Univ. researchers have identified an important enzyme pathway that helps prevent new cells from receiving too many or too few chromosomes, a condition that has been directly linked to cancer and other diseases. The team found that near the end of cell division, the enzyme Cdc14 activates Yen1, an enzyme that ensures any breaks in DNA are fully repaired before the parent cell distributes copies of the genome to daughter cells.
Unlike healthy cells, cancer cells thrive when deprived of oxygen. Tumors in low-oxygen environments tend to be more resistant to therapy and spread more aggressively to other parts of the body. Measuring tumors’ oxygen levels could help doctors make decisions about treatments, but there’s currently no way to make such measurements. However, a new sensor developed at Massachusetts Institute of Technology could change that.
Delivering chemotherapy drugs in nanoparticle form could help reduce side effects by targeting the drugs directly to the tumors. In recent years, scientists have developed nanoparticles that deliver one or two chemotherapy drugs, but it has been difficult to design particles that can carry any more than that in a precise ratio. Now Massachusetts Institute of Technology chemists have devised a new way to build such nanoparticles.
A 10-year-old girl who died of brain cancer is leaving a legacy for other sick children in a new law signed by President Barack Obama. The legislation calls for eliminating taxpayer funding for political conventions and redirecting it to pediatric research at the National Institutes of Health.
Using magnetically controlled nanoparticles to force tumor cells to "self-destruct" sounds like science fiction, but could be a future part of cancer treatment, according to new research.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go. Now, researchers are developing a better delivery method by encapsulating the drugs in nanoballoons – which are tiny modified liposomes that, upon being struck by a red laser, pop open and deliver concentrated doses of medicine.
A new understanding of proteins at the nexus of a cell’s decision to survive or die has implications for researchers who study cancer and age-related diseases, according to biophysicists at the Rice Univ.-based Center for Theoretical Biological Physics. Experiments and computer analysis of two key proteins revealed a previously unknown binding interface that could be addressed by medication.
The delicate balance between development of normal tissue and tumors depends in part upon a key molecular switch within cells, Yale School of Medicine researchers report in Science. Their findings reveal a potential mechanism used by cancer cells to recruit healthy cells to promote tumor growth and suggest new strategies to generate healthy tissue.
When cancers become advanced, tumor cells from the primary tumor can enter the bloodstream and cause metastasis at another organ with deadly effect. While researching the biological implications of CTC spread, Creatv MicroTech researchers found a group of previously unreported cells associated with primary cancer spread. These macrophage-like cells could serve as biomarkers.
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers—a higher rate of urinary toxicity or urine poisoning. The standard therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer treatment that delivers a greater dose of radiation than IMRT.
Biomedical engineering researchers have developed a new technique that uses adenosine-5’-triphosphate (ATP), the so-called “energy molecule,” to trigger the release of anti-cancer drugs directly into cancer cells. Early laboratory tests show it increases the effectiveness of drugs targeting breast cancer. The technique was developed by researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill.
About 90% of cancer deaths are caused by tumors that have spread from their original locations. This process, known as metastasis, requires cancer cells to break loose from their neighbors and from the supportive scaffold that gives tissues their structure. Cancer biologists have now discovered that certain proteins in this structure, known as the extracellular matrix, help cancer cells make their escape.
Finding treatments for advanced stage cancer isn’t easy. Therefore, early detection methods are paramount in the fight against the disease. Motivated by the opportunity to intervene as early as possible in the course of cancer, Dr. Muneesh Tewari, a Univ. of Michigan researcher, has been studying the diagnostic potential of blood-based biomarkers.
Beating cancer is all about early detection, and new research from the Univ. of South Carolina is another step forward in catching the disease early. A team of chemists is reporting a new way to detect just a few lurking tumor cells, which can be outnumbered a billion to one in the bloodstream by healthy cells.
A diverse team of scientists from Univ. of California, Los Angeles' Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.
If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient’s cancer treatment on commonly disrupted genes and pathways.
Women with estrogen-responsive breast cancer who consume soy protein supplements containing isoflavones to alleviate the side effects of menopause may be accelerating progression of their cancer, changing it from a treatable subtype to a more aggressive, less treatable form of the disease, new research suggests.
The Food and Drug Administration on Wednesday approved a cancer drug from Pharmacyclics and Janssen Biotech Inc. for a new use against a rare blood and bone marrow disease. The agency said it approved Imbruvica for patients with chronic lymphocytic leukemia who have already tried at least one other therapy.
In the U.S. about 12,500 women are diagnosed with cervical cancer a year. Out of these women, about 4,500 progress into invasive cervical cancer or the end stage of the disease. This leaves about 8,000 women a year in the U.S. that are cured through existing standard of care treatment: surgery or chemotherapy/radiation. However, chemotherapy/radiation have terrible side effects in some cases.
Pancreatic cancer is a particularly devastating disease. At least 94% of patients will die within five years, and in 2013 it was ranked as one of the top 10 deadliest cancers. Routine screenings for breast, colon and lung cancers have improved treatment and outcomes for patients with these diseases. But because little is known about how pancreatic cancer behaves, patients often receive a diagnosis when it’s already too late.
Nearly 70% of patients with advanced breast cancer experience skeletal metastasis, in which cancer cells migrate from a primary tumor into bone. While scientists are attempting to better understand metastasis in general, not much is known about how and why certain cancers spread to specific organs. Now researchers have developed a 3-D microfluidic platform that mimics the spread of breast cancer cells into a bone-like environment.
Maybe you’ve seen the movies or played with toy Transformers, those shape-shifting machines that morph in response to whatever challenge they face. It turns out that DNA-repair machines in your cells use a similar approach to fight cancer and other diseases, according to research led by scientists from Lawrence Berkeley National Laboratory.
Researchers at Oregon State Univ. have discovered a genetic function that helps one of the most important “tumor suppressor” genes to do its job and prevent cancer. Finding ways to maintain or increase the effectiveness of this gene—called Grp1-associated scaffold protein, or Grasp—could offer an important new avenue for human cancer therapies, scientists said.
Cancer drugs that recruit antibodies from the body’s own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return. A new study from Massachusetts Institute of Technology reveals a way to combat these recurrent tumors with a drug that makes them more vulnerable to the antibody treatment.
Using a novel high-throughput screening process, scientists have, for the first time, identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Glaucoma is a group of diseases that can damage the eye’s optic nerve and cause vision loss and blindness. Elevated eye pressure is the main risk factor for optic nerve damage.